Adicet Bio Seeks Reverse Split to Avoid Nasdaq Delisting

TL;DR

**ACET is doing a reverse split to stay listed on Nasdaq; it's a desperate move, but necessary to avoid being delisted.**

AI Summary

Adicet Bio, Inc. (ACET) is proposing a reverse stock split at a ratio of one-for-five to one-for-thirty to address its non-compliance with Nasdaq's minimum bid price requirement. As of November 14, 2025, ACET's closing bid price was $0.66 per share, significantly below the Nasdaq Capital Market's $1.00 per share threshold. The company received a non-compliance notice on April 7, 2025, and has an initial 180-calendar-day compliance period. The Board believes a higher stock price, achieved through the reverse split, could increase investor interest and facilitate future financings. Stockholders of record as of November 14, 2025, will vote on this proposal at a Special Meeting on December 19, 2025. The Board retains discretion to set the exact ratio and abandon the split if deemed not in the company's best interest.

Why It Matters

Adicet Bio's proposed reverse stock split is a critical move to maintain its Nasdaq listing, directly impacting investor confidence and the stock's liquidity. Failure to meet the $1.00 bid price requirement could lead to delisting, severely limiting the stock's marketability and potentially reducing its value for existing shareholders. For employees, continued listing can signal stability, while for customers, it might indirectly affect perceptions of the company's long-term viability. In the competitive biotech landscape, maintaining a public listing is crucial for attracting capital and talent, putting pressure on Adicet Bio to execute this strategy effectively.

Risk Assessment

Risk Level: high — The risk level is high because Adicet Bio's stock price was $0.66 on November 14, 2025, well below the Nasdaq $1.00 minimum bid price requirement. While a reverse split aims to increase the per-share price, it does not guarantee long-term compliance or address underlying business fundamentals, and the Board has discretion to abandon the split, leaving the delisting threat unresolved.

Analyst Insight

Investors should carefully evaluate Adicet Bio's underlying business fundamentals and pipeline, not just the stock split. Consider if the company has a viable path to sustained growth and profitability beyond merely meeting listing requirements, as a reverse split alone doesn't create value.

Key Numbers

• $0.66 — Closing bid price per share (On November 14, 2025, below Nasdaq's $1.00 requirement)
• $1.00 — Nasdaq minimum bid price requirement (Threshold for continued listing on Nasdaq Capital Market)
• 153,255,581 — Shares of common stock outstanding (As of November 14, 2025, entitled to vote)
• 180 — Calendar days (Initial compliance period provided by Nasdaq)
• 76,627,791 — Shares for quorum (Majority of outstanding shares required for Special Meeting quorum)
• 1-for-5 — Minimum reverse stock split ratio (Board's discretion range for the split)
• 1-for-30 — Maximum reverse stock split ratio (Board's discretion range for the split)
• 2025-11-14 — Record Date (Date for determining stockholders entitled to vote)
• 2025-12-19 — Special Meeting Date (Date stockholders will vote on the reverse stock split)
• 2025-04-07 — Nasdaq Notice Date (Date Adicet Bio received non-compliance notice)

Key Players & Entities

• Adicet Bio, Inc. (company) — Registrant proposing reverse stock split
• Nasdaq Capital Market (regulator) — Stock exchange with $1.00 minimum bid price requirement
• Chen Schor (person) — President, Chief Executive Officer of Adicet Bio, Inc.
• Secretary of State of the State of Delaware (regulator) — Entity where Certificate of Amendment will be filed
• Broadridge Financial Solutions, Inc. (company) — Company assisting with proxy material distribution
• Securities and Exchange Commission (regulator) — Regulatory body for filing Form 8-K

FAQ

Risk Factors

• Nasdaq Non-Compliance [high — regulatory]: Adicet Bio, Inc. received a non-compliance notice from Nasdaq on April 7, 2025, due to its closing bid price falling below the $1.00 minimum requirement. The company's closing bid price was $0.66 as of November 14, 2025. Failure to regain compliance within the initial 180-day period could lead to delisting.
• Reverse Stock Split Dilution Risk [medium — financial]: The proposed reverse stock split, with a ratio between 1-for-5 and 1-for-30, aims to increase the stock price. However, if the stock price does not sustain above the Nasdaq minimum after the split, the company may face further compliance issues and potential delisting, impacting investor confidence and future financing opportunities.
• Dependence on Clinical Trial Success [high — operational]: As a clinical-stage biotechnology company, Adicet Bio's success is heavily dependent on the outcome of its ongoing and future clinical trials for its drug candidates. Unfavorable trial results could significantly impact the company's valuation and ability to secure funding.
• Need for Future Financing [high — financial]: Adicet Bio, like many clinical-stage biotechs, will likely require substantial additional funding to advance its pipeline through clinical development and potential commercialization. The current low stock price and potential Nasdaq delisting could hinder its ability to raise capital effectively.

Industry Context

The biotechnology industry, particularly the clinical-stage segment, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like Adicet Bio rely heavily on successful clinical trials and subsequent funding rounds to advance their drug candidates. The competitive landscape is intense, with numerous companies vying for market share and investor capital.

Regulatory Implications

Adicet Bio faces immediate regulatory risk from Nasdaq regarding its minimum bid price. Failure to comply could result in delisting from the Nasdaq Capital Market, significantly impacting liquidity and investor perception. The company must also navigate the stringent FDA approval process for its therapeutic candidates.

What Investors Should Do

1. Review the Proxy Statement carefully.
2. Vote on the Reverse Stock Split Proposal.
3. Monitor the company's stock performance post-split.
4. Consider the implications of potential delisting.

Key Dates

• 2025-04-07: Nasdaq Notice of Non-Compliance — Adicet Bio received formal notification that its stock price was below Nasdaq's minimum bid price requirement, triggering a compliance period.
• 2025-11-14: Record Date — Determines which stockholders are eligible to vote at the Special Meeting. As of this date, the closing bid price was $0.66.
• 2025-11-17: Mailing of Proxy Materials — Stockholders begin receiving information about the Special Meeting and the proposed reverse stock split.
• 2025-12-19: Special Meeting of Stockholders — Stockholders will vote on the proposed reverse stock split and other matters. The outcome is critical for Nasdaq compliance.

Glossary

Reverse Stock Split

A corporate action where a company reduces the total number of its outstanding shares by combining existing shares into fewer, proportionally more valuable shares. (Adicet Bio is proposing this to increase its stock price and meet Nasdaq's minimum bid price requirement.)

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information to shareholders about matters to be voted on at a shareholder meeting. (This document outlines the proposed reverse stock split and provides the rationale and details for the shareholder vote.)

Nasdaq Capital Market

A tier of the Nasdaq stock exchange that lists smaller companies and has specific listing requirements, including a minimum bid price. (Adicet Bio is currently listed on this market and risks delisting if it fails to meet the minimum bid price requirement of $1.00.)

Restated Certificate of Incorporation

The primary governing document of a corporation, which has been amended and restated to reflect changes in the company's structure or bylaws. (An amendment to this document is required to implement the reverse stock split.)

Proxy Card

A document that authorizes a designated person (the proxy) to vote a shareholder's stock at a shareholder meeting. (Stockholders will use this to cast their vote on the reverse stock split proposal.)

Street Name Stockholders

Investors who hold their shares through a broker or other financial institution, rather than directly registering them in their own name. (These stockholders will receive voting instructions from their broker and need to follow those procedures to vote their shares.)

Year-Over-Year Comparison

This filing is a proxy statement for a special meeting focused on a reverse stock split, indicating a critical juncture for Adicet Bio. Unlike typical annual filings that would detail financial performance and strategic updates, this document primarily addresses the immediate need to comply with Nasdaq's minimum bid price requirement. Specific financial metrics like revenue, net income, and margins are not the focus here, but the underlying issue of a low stock price ($0.66 as of November 14, 2025) suggests potential challenges in market perception or operational progress that may have been present in prior periods and are now necessitating this action.

Key Financial Figures

• $0.0001 — g shares of our common stock, par value $0.0001 per share (Common Stock), into a lesser
• $1.00 — price that is greater than or equal to $1.00 per share. On November 14, 2025, the cl
• $0.66 — Stock on the Nasdaq Capital Market was $0.66 per share. The Board also believes that
• $1.00 m — f our Common Stock fails to satisfy the $1.00 minimum bid price requirement for a 30 co

Filing Documents

• acet-20251117.htm (DEF 14A) — 319KB
• img106677955_0.jpg (GRAPHIC) — 11KB
• img106677955_1.jpg (GRAPHIC) — 191KB
• img106677955_2.jpg (GRAPHIC) — 230KB
• 0001193125-25-284586.txt ( ) — 1646KB
• acet-20251117.xsd (EX-101.SCH) — 40KB
• acet-20251117_htm.xml (XML) — 1KB

From the Filing

DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Adicet Bio, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act Rules 14a-6(i)(1) and 0-11 ADICET BIO, INC. 131 Dartmouth Street, 3rd Floor Boston, Massachusetts 02116 NOTICE OF SPECIAL MEETING OF STOCKHOLDERS To be held on December 19, 2025 Notice is hereby given that the Special Meeting of Stockholders (Special Meeting) of Adicet Bio, Inc., will be held online on December 19, 2025 at 8:00 a.m. Eastern Time. You may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/ACET2025SM , where you will be able to vote electronically and submit questions. You will need the 16-digit control number included with the proxy materials being mailed to you separately in order to attend the Special Meeting. The purpose of the Special Meeting is the following: 1. To approve an amendment to our Restated Certificate of Incorporation (Certificate of Incorporation) to combine outstanding shares of our common stock, par value $0.0001 per share (Common Stock), into a lesser number of outstanding shares (the Reverse Stock Split), by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio to be set within this range by our board of directors (the Board) in its sole discretion (the Reverse Stock Split Proposal or Proposal No. 1). 2. To approve an adjournment of the Special Meeting, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes in favor of Proposal No. 1 (the Adjournment Proposal or Proposal No. 2). Only Adicet Bio, Inc. stockholders of record at the close of business on November 14, 2025, will be entitled to vote at the Special Meeting and any adjournment or postponement thereof. We are mailing to our stockholders this proxy statement and the accompanying proxy card (Proxy Materials). We plan to mail the Proxy Materials on or about November 17, 2025, which will contain instructions on how to access those documents and to cast your vote via the Internet. To be admitted to the Special Meeting and vote your shares, you must provide the 16-digit control number as provided described in the proxy card or voting instruction form at www.proxyvote.com . Please see the "General Information" section of the proxy statement that accompanies this notice for more details regarding the logistics of the virtual Special Meeting, including the ability of stockholders to submit questions during the Special Meeting, and technical details and support related to accessing the virtual platform. Your vote is important. Whether or not you are able to attend the meeting in person, it is important that your shares be represented. To ensure that your vote is recorded promptly, please vote as soon as possible, even if you plan to attend the meeting, by submitting your proxy via the Internet at the address listed on the proxy card or by signing, dating, and returning the proxy card. If your shares are held in "street name," that is, held for your account by a broker or other nominee, you will receive instructions from the holder of record that you must follow for your shares to be voted. By order of the board of directors, /s/ Chen Schor Chen Schor President, Chief Executive Officer Boston, Massachusetts November 17, 2025 TABLE OF CONTENTS Page PROXY STATEMENT 1 PROPOSAL NO. 1 – REVERSE STOCK SPLIT PROPOSAL 5 PROPOSAL NO. 2 – ADJOURNMENT PROPOSAL 15 PRINCIPAL STOCKHOLDERS 16 HOUSEHOLDING 19 STOCKHOLDER PROPOSALS 19 OTHER MATTERS 19 i ADICET BIO, INC. PROXY STATEMENT FOR THE special MEETING OF STOCKHOLDERS general information When are this Proxy Statement and the accompanying materials scheduled to be sent to stockholders? We anticipate on or about November 17, 2025, we will begin mailing this Proxy Statement and the accompanying proxy card or, for shares held in street name (i.e., held for your account by a broker or other nominee), a voting instruction form will be mailed and made available to stockholders on the Internet on or about the same date. Why did I receive a full set of the proxy materials, instead of a Notice of Internet Availability

View Full Filing

View this DEF 14A filing on SEC EDGAR